MedMen Enterprises (MedMen Enterprises) EBIT per Share : $-0.11 (TTM As of Mar. 2023)

View and export this data going back to 2018. Start your Free Trial

What is MedMen Enterprises EBIT per Share?

MedMen Enterprises's EBIT per Share for the three months ended in Mar. 2023 was $-0.02. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.11.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for MedMen Enterprises's EBIT per Share or its related term are showing as below:

MMNFQ's 3-Year EBIT Growth Rate is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 7.3
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

MedMen Enterprises's EBIT for the three months ended in Mar. 2023 was $-24.9 Mil.

MedMen Enterprises EBIT per Share Historical Data

The historical data trend for MedMen Enterprises's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedMen Enterprises EBIT per Share Chart

MedMen Enterprises Annual Data

Trend

Oct13

Oct14

Oct15

Oct16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

EBIT per Share

Get a 7-Day Free Trial

-2.34

-2.29

-1.70

-0.13

-0.12

MedMen Enterprises Quarterly Data
	Apr18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
EBIT per Share	Get a 7-Day Free Trial															-0.01	-0.08	-0.01	-	-0.02

MedMen Enterprises EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

MedMen Enterprises's EBIT per Share for the fiscal year that ended in Jun. 2022 is calculated as

	EBIT per Share		(A: Jun. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-132.378	/	1153.538
=	-0.11

MedMen Enterprises's EBIT per Share for the quarter that ended in Mar. 2023 is calculated as

	EBIT per Share		(Q: Mar. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-24.936	/	1340.935
=	-0.02

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.11

MedMen Enterprises (OTCPK:MMNFQ) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

MedMen Enterprises EBIT per Share Related Terms

Thank you for viewing the detailed overview of MedMen Enterprises's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

MedMen Enterprises (MedMen Enterprises) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » MedMen Enterprises Inc (OTCPK:MMNFQ) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

0JS:Germany MMEN:Canada

Address

10115 Jefferson Boulevard, Culver City, CA, USA, 90232

Website

https://www.medmen.com

MedMen Enterprises Inc formerly known as Ladera Ventures Corp is the preeminent cannabis company with multiple assets and operations in California, Nevada, and New York, which combined account for nearly half of North America's addressable legal market. The company owns and operates licensed cannabis facilities in cultivation, manufacturing, and retail.